rs7023146

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_004972.4(JAK2):​c.351-4240G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.618 in 152,058 control chromosomes in the GnomAD database, including 31,205 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.62 ( 31205 hom., cov: 32)

Consequence

JAK2
NM_004972.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.435

Publications

7 publications found
Variant links:
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.95).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.872 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
JAK2NM_004972.4 linkc.351-4240G>A intron_variant Intron 4 of 24 ENST00000381652.4 NP_004963.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
JAK2ENST00000381652.4 linkc.351-4240G>A intron_variant Intron 4 of 24 1 NM_004972.4 ENSP00000371067.4
JAK2ENST00000636127.1 linkc.351-4240G>A intron_variant Intron 4 of 15 5 ENSP00000489812.1

Frequencies

GnomAD3 genomes
AF:
0.618
AC:
93884
AN:
151940
Hom.:
31159
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.880
Gnomad AMI
AF:
0.578
Gnomad AMR
AF:
0.554
Gnomad ASJ
AF:
0.594
Gnomad EAS
AF:
0.447
Gnomad SAS
AF:
0.513
Gnomad FIN
AF:
0.563
Gnomad MID
AF:
0.551
Gnomad NFE
AF:
0.504
Gnomad OTH
AF:
0.591
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.618
AC:
93989
AN:
152058
Hom.:
31205
Cov.:
32
AF XY:
0.617
AC XY:
45816
AN XY:
74308
show subpopulations
African (AFR)
AF:
0.880
AC:
36557
AN:
41542
American (AMR)
AF:
0.554
AC:
8465
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.594
AC:
2061
AN:
3468
East Asian (EAS)
AF:
0.448
AC:
2317
AN:
5174
South Asian (SAS)
AF:
0.513
AC:
2472
AN:
4820
European-Finnish (FIN)
AF:
0.563
AC:
5929
AN:
10532
Middle Eastern (MID)
AF:
0.521
AC:
152
AN:
292
European-Non Finnish (NFE)
AF:
0.504
AC:
34260
AN:
67934
Other (OTH)
AF:
0.593
AC:
1251
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1642
3284
4926
6568
8210
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
738
1476
2214
2952
3690
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.595
Hom.:
4375
Bravo
AF:
0.626
Asia WGS
AF:
0.553
AC:
1918
AN:
3472

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.95
CADD
Benign
0.70
DANN
Benign
0.50
PhyloP100
-0.43
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs7023146; hg19: chr9-5040163; API